Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6977389 | 0.93 | OPRD1 (0.44) | PKMGAATSHRCCR3OPRD1 | |
| SCHEMBL6970176 | 0.89 | OPRD1 (0.45) | CCR3OPRD1OPRK1 | |
| SCHEMBL6981816 | 0.89 | OPRD1 (0.48) | GAACCR3OPRD1OPRK1OPRM1 | |
| SCHEMBL6967490 | 0.89 | OPRD1 (0.41) | CCR3OPRD1OPRK1OPRM1DRD2 | |
| SCHEMBL6971806 | 0.89 | OPRD1 (0.42) | TSHRCCR3OPRD1OPRK1SIGMAR1 | |
| SCHEMBL6968136 | 0.88 | OPRD1 (0.44) | TSHRCCR3OPRD1OPRK1 | |
| SCHEMBL6979779 | 0.86 | ADRA1A (0.41) | CCR3OPRD1OPRK1 | |
| SCHEMBL6967499 | 0.86 | CHRM2 (0.45) | PKMGAAOPRD1OPRK1 | |
| SCHEMBL6965179 | 0.86 | OPRD1 (0.50) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6974540 | 0.86 | OPRD1 (0.40) | CCR3OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566376-B1 | For therapy of chemokine receptor related diseases and conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA UK LIMITED (GB) | 2003-05-20 | — | — | US | claimed |
| EP-1202984-B1 | DIPHENYL-PIPERIDINE DERIVATE | ASTRAZENECA UK LTD (GB) | 2003-03-05 | — | — | EP | claimed |
| EP-1202984-A1 | NOVEL DIPHENYL-PIPERIDINE DERIVATE | AstraZeneca UK Limited (GB) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005782-A1 | NOVEL DIPHENYL-PIPERIDINE DERIVATE | ASTRAZENECA UK LIMITED (GB) | 2001-01-25 | — | — | WO | claimed |
| US-6566376-B1 | For therapy of chemokine receptor related diseases and conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA UK LIMITED (GB) | 2003-05-20 | — | — | US | disclosed |
| EP-1202984-B1 | DIPHENYL-PIPERIDINE DERIVATE | ASTRAZENECA UK LTD (GB) | 2003-03-05 | — | — | EP | disclosed |